查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010979

腦生物標記市場：按生物標記類型、疾病、檢體類型、技術和最終用戶分類－2026年至2032年全球市場預測

Brain Biomarkers Market by Biomarker Type, Disease Indication, Sample Type, Technology, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，腦生物標記市場價值將達到 125 億美元，到 2026 年將成長至 146.4 億美元，到 2032 年將達到 407.4 億美元，年複合成長率為 18.37%。

主要市場統計數據
基準年 2025 125億美元
預計年份：2026年 146.4億美元
預測年份 2032 407.4億美元
複合年成長率 (%) 18.37%

綜合介紹塑造腦生物標記開發和傳播未來的科學、臨床、監管和商業性基礎。

隨著分子生物學、成像技術和計算分析的融合，腦生物標記的探索和商業化正在迅速推進，從而催生出更精準的診斷和預後工具。近期科學突破提高了神經退化性疾病疾病和急性神經系統疾病候選生物標記的敏感性和特異性，同時，檢體處理、數位診斷和法規結構的同步發展也使得臨床檢驗流程更加高效。本文概述了關鍵促進因素、相關人員的需求以及核心科學範式，旨在為研究人員、臨床醫生、投資者和產業領導者提供策略決策支援。

對加速多模態腦生物標記檢驗和臨床應用的技術、監管和合作變革的融合進行了詳細分析。

在腦生物標記領域，正在發生多項變革性變化，這些變化正在重新定義研究重點和商業化路徑。首先，精準醫療的需求正推動該領域從基於單一分析物的測量轉向結合遺傳資訊、蛋白質體學、代謝物和影像學資訊的多模態態特徵。分析靈敏度的提高和更豐富的縱向資料集為這一整合趨勢提供了支持，這些因素共同增強了生物標記組合和演算法決策支援工具的臨床意義。

2025 年美國關稅調整對腦生物標記舉措的採購、供應鏈韌性和商業化計畫的營運和策略影響。

政策環境正在影響供應鏈、試劑成本、儀器採購和跨境合作，而美國近期針對2025年實施的關稅調整，也為價值鏈上的相關人員帶來了新的營運考量。關稅調整影響了進口儀器組件、特殊試劑和實驗室耗材，迫使採購團隊重新評估其籌資策略和成本結構。為此，許多機構加強了供應商多元化，透過談判簽訂長期合約來降低價格波動風險，並加快了供應商選擇流程，以確保關鍵檢測的連續性。

整合全面的細分，以識別生物標記類型、適應症、檢體基質、技術和最終用戶的交集，並確定開發和部署的優先事項。

一套精細的細分框架清晰地展現了科學機會與商業性需求之間的交集。就生物標記的類型而言，遺傳標記包括基因表現標記、 微型RNA標記和單核苷酸多態性（SNP）標誌物，每種標記物在闡明疾病機制和預測分析方面都具有獨特的優勢。諸如電腦斷層掃描（CT）、磁振造影（MRI）和正子斷層掃描（PET）等影像技術能夠提供高空間解析度的解剖和功能數據，是對分子層級測量的補充。代謝物檢測涵蓋脂質代謝物和小分子代謝物，可以反映動態的生化狀態和代謝異常。同時，在腦脊髓液、血漿和唾​​液中檢測的蛋白質生物標記具有不同的靈敏度和可及性，適用於臨床應用。

影響美洲、歐洲、中東、非洲和亞太地區臨床檢驗、監管流程和商業化策略的區域趨勢。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的科學研究合作、監管預期、報銷環境和基礎設施投資都產生了重大影響。在美洲，健全的臨床研究網路和完善的支付體系為後期檢驗和支付方合作提供了有利環境，而大量的私人和公共資金支持著轉化研究和技術商業化。該地區也聚集了許多先進的診斷實驗室和大學附屬醫院，能夠進行複雜的多中心研究並產生真實世界數據（REW）。

策略競爭分析表明，平台整合、夥伴關係和嚴格的臨床檢驗是腦生物標記生態系統中主要參與者的關鍵差異化因素。

在腦生物標記生態系統中，主要企業正透過整合平台策略、策略夥伴關係以及對臨床檢驗的投資來展現其真實世界價值，從而實現差異化競爭。成功的企業將深厚的檢測開發專業知識與可擴展的生產流程和監管經驗相結合，以應對複雜的核准和報銷環境。診斷公司、設備製造商、製藥公司和學術機構之間的合作關係能夠加速獲取臨床檢體，擴大檢驗隊列，並為與治療項目相關的伴隨診斷的共同開發鋪平道路。

為領導者提供實用建議，以協調證據產生、供應鏈韌性和個人化商業化策略，從而加速臨床部署。

產業領導者應優先產生與臨床決策要點和支付方價值框架相符的證據，以加速生物標記的應用和報銷。透過設計前瞻性效用研究，展示基於生物標記的決策如何改善患者預後或最佳化資源利用，可以強化價值主張並降低提案障礙。同時，各機構應投資於結合基因、蛋白質、代謝物和影像數據的多模態檢驗策略，以提高診斷準確性，並為治療決策提供更豐富的背景資訊。

高度透明的調查方法，結合一手訪談、二手文獻回顧和嚴謹的分析框架，確保了可重複性和可操作性的見解。

本報告整合了第一手和第二手研究、專家訪談以及嚴謹的方法論框架，以確保提供可靠且透明的洞見。第一手研究包括對臨床研究人員、檢查室管理人員、行業高管和保險公司進行的結構化訪談，從而提供關於營運挑戰、檢驗重點和應用促進因素的實證見解。第二手研究則利用同儕審查文獻、監管指導文件和技術白皮書，全面檢驗診斷技術應用的技術性能特徵和歷史案例研究。

結論整合強調了實現生物標記影響所必需的綜合證據策略、營運靈活性和跨部門合作。

總之，腦生物標記領域正處於一個轉折點，科學進步、技術成熟和政策環境的變化共同為改善多種神經系統疾病的診斷、監測和治療方法研發創造了實際機會。要充分發揮這一潛力，需要精心整合多模態數據，設計能夠證明臨床效用的可操作檢驗方案，並建立一個能夠適應供應鏈和政策波動的穩健運作框架。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：腦生物標記市場－依生物標記類型分類

  • 基因
    • 基因表現標記
    • miRNA標記物
    • SNP標記
  • 診斷影像
    • CT
    • MRI
    • PET
  • 代謝物
    • 脂質代謝物
    • 小分子代謝物
  • 蛋白質
    • 腦脊髓液（CSF）蛋白
    • 電漿番茄
    • 唾液蛋白

第9章：腦生物標記市場：依疾病指徵分類

  • 阿茲海默症
  • 癲癇
  • 多發性硬化症
  • 帕金森氏症
  • 中風

第10章：依檢體類型分類的腦生物標記市場

  • 血
    • 電漿
    • 血清
  • 腦脊髓液
  • 唾液
  • 尿

第11章 腦生物標記市場：依技術分類

  • 層析法
  • 免疫檢測
  • 質譜分析
  • 次世代定序
  • PCR

第12章 腦生物標記市場：依最終用戶分類

  • 合約研究機構
  • 診斷檢測實驗室
  • 醫院
  • 製藥公司
  • 研究機構

第13章 腦生物標記市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 腦生物標記市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 腦生物標記市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國腦生物標記市場

第17章：中國腦生物標記市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • ADx NeuroSciences NV
  • Amprion, Inc.
  • Banyan Biomarkers, Inc.
  • Biogen Inc.
  • C2N Diagnostics, LLC
  • DiaSorin SpA
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Fujirebio Diagnostics, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Merck KGaA
  • Mesoscale Discovery, LLC
  • Novartis AG
  • Quanterix Corporation
  • Quretec Ltd.
  • Roche Holding AG
  • Siemens Healthineers AG
Product Code: MRR-43150DF82D01

The Brain Biomarkers Market was valued at USD 12.50 billion in 2025 and is projected to grow to USD 14.64 billion in 2026, with a CAGR of 18.37%, reaching USD 40.74 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 12.50 billion
Estimated Year [2026] USD 14.64 billion
Forecast Year [2032] USD 40.74 billion
CAGR (%) 18.37%

An integrated introduction outlining the scientific, clinical, regulatory, and commercial foundations shaping the future of brain biomarker development and adoption

The landscape of brain biomarker research and commercialization is rapidly advancing as molecular biology, imaging modalities, and computational analytics converge to create more precise diagnostic and prognostic tools. Recent scientific breakthroughs have improved the sensitivity and specificity of candidate biomarkers across neurodegenerative and acute neurological conditions, while parallel progress in sample processing, digital diagnostics, and regulatory frameworks is enabling more streamlined clinical validation pathways. This introduction frames the key drivers, stakeholder needs, and core scientific paradigms that inform strategic decisions for researchers, clinicians, investors, and industry leaders.

Understanding this field requires an integrated perspective that connects technology platforms with clinical endpoints and end-user adoption dynamics. Advances in genetic profiling, expanded imaging capabilities, and enhanced biofluid assays are increasingly capable of delivering clinically actionable insights earlier in disease trajectories. At the same time, healthcare systems are under pressure to prioritize diagnostics that improve outcomes, reduce cost of care, and support personalized therapeutic approaches.

This section sets the stage for the executive summary by outlining how converging scientific, regulatory, and commercial forces are reshaping priorities. It highlights the importance of cross-disciplinary collaboration, robust validation standards, and strategic investments to translate promising biomarkers from discovery into routine clinical use. By establishing these foundational themes, the reader can better interpret subsequent analysis on shifts in the landscape, segmentation nuances, regional dynamics, company strategies, and actionable recommendations.

Detailed analysis of converging technological, regulatory, and collaborative shifts that are accelerating multimodal brain biomarker validation and clinical adoption

The brain biomarker landscape is experiencing several transformative shifts that are redefining research priorities and commercialization pathways. First, precision medicine imperatives are moving the field beyond single-analyte readouts toward multimodal signatures that combine genetic, proteomic, metabolite, and imaging-derived information. This integrative trend is supported by improved analytic sensitivity and richer longitudinal datasets, which together elevate the clinical relevance of biomarker panels and algorithmic decision-support tools.

Second, technology maturation is accelerating throughput and reducing assay costs, thereby enabling broader deployment in both research and clinical settings. High-resolution imaging protocols and next generation sequencing platforms have become more accessible, while mass spectrometry and advanced immunoassays are delivering higher reproducibility for biofluid-based markers. These capabilities are complemented by digital health tools that facilitate remote sample collection and real-world data capture, strengthening evidence generation across diverse patient cohorts.

Third, regulatory approaches and payer considerations are shifting to accommodate novel diagnostics that demonstrate clear clinical utility. Health systems and payers are increasingly focused on value-based evidence linking biomarker use to improved patient outcomes, pathway efficiencies, or cost offsets. Consequently, sponsors are adapting study designs to emphasize prospective clinical utility, health economics, and implementation feasibility.

Finally, collaborative models are emerging as essential to accelerate validation and adoption. Public-private partnerships, data consortia, and multi-center clinical networks are addressing reproducibility challenges and enabling larger, more diverse validation cohorts. Taken together, these shifts create a dynamic environment in which innovation, evidence rigor, and practical deployment strategies must align to realize the full potential of brain biomarkers.

Operational and strategic ramifications of recent United States tariff adjustments in 2025 shaping procurement, supply chain resilience, and commercialization planning for brain biomarker initiatives

The policy environment influences supply chains, reagent costs, instrument procurement, and cross-border collaborations, and recent tariff changes in the United States for 2025 introduced new operational considerations for stakeholders across the value chain. Tariff adjustments affected imported instrumentation components, specialized reagents, and laboratory consumables, prompting procurement teams to reassess sourcing strategies and cost structures. In response, many organizations intensified supplier diversification, negotiated long-term contracts to mitigate price volatility, and accelerated vendor qualification processes to maintain continuity of critical assays.

Supply chain recalibration extended to international partnerships, where collaborative research programs reassessed timelines and logistical workflows to account for potential customs delays and higher landed costs. These operational adjustments had a downstream effect on research throughput and pilot study timelines, particularly for programs reliant on imported imaging hardware, sequencing reagents, and high-sensitivity assay kits. Consequently, study planners prioritized critical-path items and adopted phased validation approaches to preserve momentum while containing near-term cost pressures.

Tariff-induced shifts also highlighted the strategic value of domestic manufacturing and local partnerships. Stakeholders exploring co-development and contract manufacturing agreements sought to build redundancy and reduce exposure to trade policy fluctuations. Where local supply alternatives were limited, organizations invested in robust inventory strategies and instituted adaptive budgeting to absorb episodic cost increases without compromising study integrity.

Finally, these trade policy dynamics underscored the need for flexible commercialization strategies. Companies seeking to enter or expand in the U.S. market recalibrated pricing models, refined value propositions to justify list pricing changes, and engaged payers earlier to reinforce reimbursement narratives. In sum, the 2025 tariff adjustments catalyzed pragmatic operational shifts and encouraged longer-term investments in supply chain resilience and localized capabilities.

Comprehensive segmentation synthesis revealing where biomarker type, indication, sample matrix, technology, and end user converge to prioritize development and adoption pathways

A nuanced segmentation framework brings clarity to where scientific opportunity and commercial traction intersect. Considering biomarker type, genetic markers encompass gene expression markers, microRNA markers, and single nucleotide polymorphism markers, each offering distinct advantages in terms of disease mechanism insight and potential for predictive analytics. Imaging modalities including computed tomography, magnetic resonance imaging, and positron emission tomography deliver spatially resolved anatomical and functional data that complement molecular readouts. Metabolite assays span lipid metabolites and small molecule metabolites, which can reflect dynamic biochemical states and metabolic dysregulation, while protein-based biomarkers measured in cerebrospinal fluid, plasma, and saliva offer varied sensitivity and accessibility profiles for clinical use.

When evaluating disease indications, priority areas such as Alzheimer's disease, epilepsy, multiple sclerosis, Parkinson's disease, and stroke illustrate diverse validation pathways and clinical endpoints. Each indication presents unique requirements for diagnostic accuracy, longitudinal monitoring, and therapeutic impact, shaping both technical development and clinical study design. Sample type segmentation further refines feasibility and adoption considerations: blood-based approaches, including plasma and serum, offer minimally invasive sampling suitable for broader screening and longitudinal monitoring, while cerebrospinal fluid provides proximity to central nervous system pathology and greater analytical sensitivity. Saliva and urine represent convenient matrices for decentralized collection but often require enhanced assay sensitivity to reach clinical utility.

Technology platform selection matters for analytical performance and scalability. Chromatography techniques such as HPLC and UHPLC, immunoassays including ELISA and lateral flow assays, mass spectrometry variants like GC-MS and LC-MS, next generation sequencing approaches encompassing targeted and whole genome sequencing, and PCR modalities including digital PCR and qPCR each present trade-offs in throughput, sensitivity, and regulatory maturity. End-user segmentation comprising contract research organizations, diagnostic laboratories, hospitals, pharmaceutical companies, and research institutes shapes commercialization and service delivery strategies, as adoption timelines and procurement processes differ substantially across these buyer groups. Integrating these layers of segmentation reveals prioritized development pathways where modality, indication, sample type, and technology align to achieve feasible clinical and commercial outcomes.

Regional dynamics shaping clinical validation, regulatory pathways, and commercialization strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics materially influence research collaborations, regulatory expectations, reimbursement environments, and infrastructure investments across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, robust clinical research networks and established payer systems provide a conducive environment for late-stage validation and payer engagement, while significant private and public funding streams support translational initiatives and technology commercialization. This region also exhibits substantial concentration of advanced diagnostic laboratories and academic medical centers that can execute complex multi-center studies and real-world evidence generation.

Europe, the Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts, centralized health technology assessment frameworks, and diverse healthcare delivery models shape adoption pathways. Several markets within this region prioritize early diagnostic interventions and national screening programs, creating opportunities for validated biomarkers that demonstrate population-level benefit. Meanwhile, emerging markets across the Middle East & Africa are rapidly building diagnostic infrastructure and forming strategic partnerships to access advanced technologies.

Asia-Pacific is characterized by substantial investment in biotech and diagnostic manufacturing, fast-growing clinical trial capacity, and a rapidly expanding patient population. Regulatory reforms and initiatives to strengthen local manufacturing are accelerating market entry for novel diagnostics, while digital health adoption and telemedicine expansion support decentralized testing and longitudinal patient monitoring. Cross-border collaborations between research institutes and industry partners in the region are enhancing access to diverse patient cohorts and facilitating accelerated validation of biomarkers across different genetic and environmental backgrounds.

Across all regions, stakeholders must tailor evidence generation, regulatory strategy, and commercialization plans to local payer expectations, clinical practice patterns, and infrastructure capabilities. Recognizing these distinctions enables targeted market entry approaches and more effective global coordination of multi-site clinical programs.

Strategic competitive analysis highlighting how platform integration, partnerships, and rigorous clinical validation differentiate leading players in the brain biomarker ecosystem

Key companies operating in the brain biomarker ecosystem are differentiating through integrated platform strategies, strategic partnerships, and investment in clinical validation to demonstrate real-world value. Successful organizations combine deep domain expertise in assay development with scalable manufacturing processes and regulatory know-how to navigate complex approval and reimbursement landscapes. Collaborative alliances between diagnostics firms, instrument manufacturers, pharmaceutical sponsors, and academic centers accelerate access to clinical samples, expand validation cohorts, and create co-development pathways for companion diagnostics linked to therapeutic programs.

Leadership strategies also emphasize portfolio diversification across modalities to hedge technical risk and address a broader set of disease indications. Companies that invest in modular, interoperable platforms - for example, assays that can be adapted across CSF, plasma, or saliva matrices, or analytical pipelines that harmonize imaging and molecular data - position themselves to serve multiple customers and use cases. In addition, firms that demonstrate transparent analytical validation and publish peer-reviewed performance data foster greater clinician and payer trust, smoothing adoption hurdles.

Smaller, innovation-driven companies often focus on niche assays or enabling technologies such as novel reagents, algorithms, or sample preservation solutions, creating acquisition or licensing targets for larger players. Meanwhile, established diagnostic and instrument companies leverage global distribution networks and regulatory experience to scale validated solutions rapidly. Across the competitive landscape, the balance between internal R&D, external partnerships, and strategic M&A determines speed to market and ability to achieve sustainable commercial traction.

Actionable recommendations for leaders to align evidence generation, supply chain resilience, and tailored commercialization strategies that accelerate clinical adoption

Industry leaders should prioritize evidence generation that aligns with clinical decision points and payer value frameworks to accelerate adoption and reimbursement. Designing prospective utility studies that demonstrate how biomarker-informed decisions improve patient outcomes or optimize resource use will strengthen value propositions and reduce adoption friction. Simultaneously, organizations should invest in multimodal validation strategies that combine genetic, protein, metabolite, and imaging data to enhance diagnostic precision and provide richer context for therapeutic decision-making.

Operationally, companies must build resilient supply chains and flexible manufacturing arrangements to mitigate policy and trade-related disruptions. Localized production capabilities, qualified secondary suppliers, and dynamic inventory models will minimize the impact of external shocks and preserve continuity for critical assays. In parallel, strengthening data interoperability and standardized reporting will make it easier for clinical laboratories and health systems to integrate new biomarkers into existing workflows and electronic health record systems.

Commercially, stakeholders should tailor go-to-market strategies to specific end-user needs, recognizing that hospitals, diagnostic labs, research institutes, contract research organizations, and pharmaceutical companies require different evidence packages, service models, and pricing approaches. Early engagement with payers and health technology assessment bodies can refine study endpoints and evidence generation plans to align with reimbursement criteria. Finally, leaders should pursue strategic collaborations and consortium participation to access diverse patient cohorts, share validation costs, and accelerate consensus on clinical utility standards.

Transparent research methodology combining primary interviews, secondary literature review, and rigorous analytic frameworks to ensure reproducible and actionable insights

This report synthesizes primary and secondary research, expert interviews, and rigorous methodological frameworks to ensure robust and transparent findings. Primary research included structured interviews with clinical investigators, laboratory directors, industry executives, and payers, providing grounded insights into operational challenges, validation priorities, and adoption drivers. Secondary research drew upon peer-reviewed literature, regulatory guidance documents, and technology white papers to triangulate technical performance characteristics and historical precedent for diagnostic adoption.

Analytical methods included qualitative thematic analysis of stakeholder interviews, cross-validation of technology capability claims against published analytical validation studies, and scenario-based assessment of operational impacts arising from policy changes. Special attention was paid to the reproducibility of assay performance across sample matrices and sites, and to the alignment of clinical endpoints with regulatory and payer evidence expectations. The methodology emphasized transparency: criteria for study inclusion, interview protocols, and analytic assumptions are documented in appendices to support reproducibility and allow readers to assess applicability to their own programs.

Where appropriate, sensitivity analyses explored alternative operational pathways and evidence strategies to highlight risk mitigations and strategic trade-offs. The combined approach ensures that recommendations reflect both empirical data and practical feasibility, providing stakeholders with a rigorous foundation for planning scientific programs, clinical validation, and commercialization tactics.

Concluding synthesis emphasizing the imperative for integrated evidence strategies, operational agility, and cross-sector collaboration to realize biomarker impact

In conclusion, the brain biomarker field stands at an inflection point where scientific advances, technological maturity, and evolving policy environments create tangible opportunities to improve diagnosis, monitoring, and therapeutic development across multiple neurological conditions. Realizing this potential requires deliberate integration of multimodal data, pragmatic validation designs that demonstrate clinical utility, and resilient operational frameworks that accommodate supply chain and policy variability.

Strategic alignment among developers, clinical research networks, payers, and healthcare providers will accelerate translation from promising markers to routine clinical practice. Investments in interoperable platforms, rigorous analytical validation, and early payer engagement will be essential to secure adoption and reimbursement. Additionally, regional strategies tailored to local regulatory expectations and infrastructure capacities will enhance global deployment prospects.

Ultimately, organizations that combine scientific rigor with operational foresight and collaborative partnerships will lead the next wave of innovation in brain biomarkers. The path forward is collaborative and evidence-driven, and stakeholders that prioritize value for patients and health systems will unlock the greatest clinical and commercial impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Biomarkers Market, by Biomarker Type

  • 8.1. Genetic
    • 8.1.1. Gene Expression Markers
    • 8.1.2. Mirna Markers
    • 8.1.3. Snp Markers
  • 8.2. Imaging
    • 8.2.1. CT
    • 8.2.2. MRI
    • 8.2.3. PET
  • 8.3. Metabolite
    • 8.3.1. Lipid Metabolites
    • 8.3.2. Small Molecule Metabolites
  • 8.4. Protein
    • 8.4.1. CSF Proteins
    • 8.4.2. Plasma Proteins
    • 8.4.3. Saliva Proteins

9. Brain Biomarkers Market, by Disease Indication

  • 9.1. Alzheimer's Disease
  • 9.2. Epilepsy
  • 9.3. Multiple Sclerosis
  • 9.4. Parkinson's Disease
  • 9.5. Stroke

10. Brain Biomarkers Market, by Sample Type

  • 10.1. Blood
    • 10.1.1. Plasma
    • 10.1.2. Serum
  • 10.2. Cerebrospinal Fluid
  • 10.3. Saliva
  • 10.4. Urine

11. Brain Biomarkers Market, by Technology

  • 11.1. Chromatography
  • 11.2. Immunoassay
  • 11.3. Mass Spectrometry
  • 11.4. Next Generation Sequencing
  • 11.5. PCR

12. Brain Biomarkers Market, by End User

  • 12.1. Contract Research Organizations
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals
  • 12.4. Pharmaceutical Companies
  • 12.5. Research Institutes

13. Brain Biomarkers Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Brain Biomarkers Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Brain Biomarkers Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Brain Biomarkers Market

17. China Brain Biomarkers Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. ADx NeuroSciences NV
  • 18.7. Amprion, Inc.
  • 18.8. Banyan Biomarkers, Inc.
  • 18.9. Biogen Inc.
  • 18.10. C2N Diagnostics, LLC
  • 18.11. DiaSorin S.p.A.
  • 18.12. Eli Lilly and Company
  • 18.13. F. Hoffmann-La Roche AG
  • 18.14. Fujirebio Diagnostics, Inc.
  • 18.15. Janssen Pharmaceuticals, Inc.
  • 18.16. Merck KGaA
  • 18.17. Mesoscale Discovery, LLC
  • 18.18. Novartis AG
  • 18.19. Quanterix Corporation
  • 18.20. Quretec Ltd.
  • 18.21. Roche Holding AG
  • 18.22. Siemens Healthineers AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRAIN BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRAIN BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENE EXPRESSION MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENE EXPRESSION MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GENE EXPRESSION MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MIRNA MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MIRNA MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MIRNA MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SNP MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SNP MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SNP MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LIPID METABOLITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LIPID METABOLITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY LIPID METABOLITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SMALL MOLECULE METABOLITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SMALL MOLECULE METABOLITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SMALL MOLECULE METABOLITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CSF PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CSF PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CSF PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY STROKE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY STROKE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CEREBROSPINAL FLUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CEREBROSPINAL FLUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CHROMATOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CHROMATOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. GCC BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. GCC BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. GCC BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 224. GCC BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 225. GCC BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 226. GCC BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 227. GCC BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 228. GCC BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. GCC BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 230. GCC BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. GCC BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. G7 BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. G7 BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. G7 BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 257. G7 BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 258. G7 BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 259. G7 BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 260. G7 BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 261. G7 BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. G7 BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 263. G7 BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 264. G7 BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. NATO BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 266. NATO BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. NATO BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 268. NATO BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 269. NATO BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 270. NATO BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 271. NATO BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 272. NATO BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. NATO BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 274. NATO BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. NATO BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL BRAIN BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA BRAIN BIOMARKERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA BRAIN BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA BRAIN BIOMARKERS MARKET SIZE, BY GENETIC, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA BRAIN BIOMARKERS MARKET SIZE, BY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA BRAIN BIOMARKERS MARKET SIZE, BY METABOLITE, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA BRAIN BIOMARKERS MARKET SIZE, BY PROTEIN, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA BRAIN BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA BRAIN BIOMARKERS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA BRAIN BIOMARKERS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA BRAIN BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA BRAIN BIOMARKERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)